The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation

Journal of Neurology

Volumn 245, Issue 4, 1998, Pages 223-230

  Jorga, Karin ^a   Fotteler, Barbel ^a   Sȩdek, Greg ^a   Nielsen, Thorkild ^a   Aitken, John ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Catechol O methyltransferase inhibition; Levodopa carbidopa; Parkinson's disease; Pharmacokinetics; Tolcapone

Indexed keywords

ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; LEVODOPA; TOLCAPONE; TRANSFERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTIPARKINSON AGENTS; BENZOPHENONES; BIOLOGICAL AVAILABILITY; CARBIDOPA; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE;

EID: 0031899068     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150050209     Document Type: Article

References (17)

1. Calne DB (1993) Treatment of Parkinson's disease. N Engl J Med 329:1021-1027
2. Contin M, Riva R, Albani F, Baruzzi A (1996) Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 30:463-481
3. Dingemanse J, Jorga KM, Schmitt M, Gieschke R, Fotteler B, Zürcher G, Da Prada M, Brummelen P van (1995) Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 57:508-517
4. Dingemanse J, Jorga K, Zürcher G, Schmitt M, Sedek G, Da Prada M, Brummelen P van (1995) Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40:253-262
5. Dingemanse J, Jorga K, Zürcher G, Fotteler B, Sedek G, Nielsen T, Brummelen P van (1996) Multiple-dose clinical pharmacology of the catechol-O-methyltransferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 50:47-55
6. Goetz CG, Tanner CM, Glanyz RH, Klawans HL (1985) Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 35:749-751
7. Jorga KM, Sedek G (1995) Effect of the novel COMT-inhibitor tolcapone on L-dopa pharmacokinetics when combined with different Sinemet formulations. Neurology 45:A291
8. Jorga K, Dingemanse J, Fotteler B, Zürcher G (1993) Pharmacokinetics-pharmacodynamics of a novel COMT inhibitor during multiple dosing regimens. Clin Pharmacol Ther 53:11-40
9. Jorga KM, Dingemanse J, Fotteler B, Schmitt M, Zürcher G, Da Prada M (1994) Effect of a novel COMT-inhibitor on L-dopa pharmacokinetics when combined with different MADOPAR formulations. New Trends Clin Neuropharmacol 8:274
10. Kaakkola S, Mannisto P, Nissinen E, et al (1985) The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa. Acta Neurol Scand 72:385-391
11. Kurth MC, Adler CH, Saint Hilaire M, Singer C, Waters CH, LeWitt P, Chernik DA, Dorflinger EE, Yoo K, The Tolcapone Fluctuator Study Group I (1997) Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multi-center, double-blind, randomized, placebo-controlled trial. Neurology 48:81-87
12. LeWitt PA (1992) Treatment strategies for extension of levodopa effect. Neurol Clin 10:511-526
13. Merello M, Lees AJ, Webster R, et al (1994) Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57:186-189
14. Poewe W, Kleedorfer B, Wagner M, et al (1993) Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease: long-term follow-up in 18 patients. Adv Neurol 60:656-659
15. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN (1994) Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 44:2685-2688
16. Timm U, Erdin R (1992) Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 308:93-100
17. Tolosa ES, Valldeoriola F, Martí MJ (1994) New and emerging strategies for improving levodopa treatment. Neurology 44 [Suppl 6]:S35-S44